MKI67 and neoplasm: Consistent with the in vivo results, immunohistochemistry staining of the proliferation marker Ki67 and TUNEL assays revealed that tumours derived from the combined treatment group had the lowest proliferation activity and the highest apoptotic rate compared with the single treatment of OICR-9429 or cisplatin or the control (Fig. 4d and e).